Valuation: TapImmune Inc

Market Cap 18.76M 16.55M 15.66M 14.2M 26.63M 1.8B 26.89M 188M 72.41M 919M 70.43M 68.9M 2.96B P/E 2026 *
-1.9x
P/E 2027 * -1.28x
Enterprise Value 18.76M 16.55M 15.66M 14.2M 26.63M 1.8B 26.89M 188M 72.41M 919M 70.43M 68.9M 2.96B EV / Sales 2026 *
4.42x
EV / Sales 2027 * 0.93x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 01/05/2023
Chief Operating Officer 36 01/12/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 17/10/2018
Chairman 65 24/05/2022
Director/Board Member 62 06/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 18.76M
-0.03%+6.41%+11.83%+38.36% 49.06B
-0.69%-0.15%+49.23%+37.07% 44.6B
+1.67%+5.89%+343.27%+637.77% 43.24B
-0.41%-0.24%+10.32%+104.14% 41.73B
+0.34%-1.38%+5.53%+47.36% 29.93B
+0.96%-1.33%+24.18%+156.82% 17.19B
-2.56%+6.43%+4.56% - 15.35B
-3.20%-2.38%+25.00%+43.67% 15.54B
-0.77%-3.81% - - 15.11B
Average -0.00%+1.76%+59.24%+152.17% 30.19B
Weighted average by Cap. -0.13%+2.17%+74.38%+166.81%

Financials

2026 *2027 *
Net sales 4.24M 3.74M 3.54M 3.21M 6.02M 407M 6.08M 42.49M 16.38M 208M 15.93M 15.58M 669M 20.19M 17.81M 16.85M 15.29M 28.66M 1.94B 28.94M 202M 77.93M 989M 75.8M 74.15M 3.18B
Net income -11.84M -10.45M -9.88M -8.96M -16.8M -1.14B -16.97M -119M -45.69M -580M -44.45M -43.48M -1.87B -18.09M -15.97M -15.11M -13.7M -25.68M -1.74B -25.94M -181M -69.84M -886M -67.93M -66.46M -2.85B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-